Madopar Depot 100+25 mg depotkapsler, hårde Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

madopar depot 100+25 mg depotkapsler, hårde

roche pharmaceuticals a/s - benserazidhydrochlorid, levodopa - depotkapsler, hårde - 100+25 mg

Madopar Depot 100+25 mg depotkapsler, hårde Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

madopar depot 100+25 mg depotkapsler, hårde

orifarm a/s - benserazidhydrochlorid, levodopa - depotkapsler, hårde - 100+25 mg

Madopar Quick 50 + 12,5 mg dispergible tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

madopar quick 50 + 12,5 mg dispergible tabletter

paranova danmark a/s - benserazidhydrochlorid, levodopa - dispergible tabletter - 50 + 12,5 mg

Madopar Quick 125 100+25 mg dispergible tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

madopar quick 125 100+25 mg dispergible tabletter

roche pharmaceuticals a/s - benserazidhydrochlorid, levodopa - dispergible tabletter - 100+25 mg

Madopar Quick 62,5 50 + 12,5 mg dispergible tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

madopar quick 62,5 50 + 12,5 mg dispergible tabletter

roche pharmaceuticals a/s - benserazidhydrochlorid, levodopa - dispergible tabletter - 50 + 12,5 mg

Qtrilmet Den Europæiske Union - dansk - EMA (European Medicines Agency)

qtrilmet

astrazeneca ab - metformin hydrochlorid, saxagliptin, dapagliflozin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - qtrilmet er indiceret hos voksne i alderen 18 år og ældre med type 2-diabetes mellitus:at forbedre glykæmisk kontrol, når metformin med eller uden sulphonylurea (su) og enten saxagliptin eller dapagliflozin ikke giver tilstrækkelig glykæmisk kontrol. når du allerede er i behandling med metformin og saxagliptin og dapagliflozin.

Dapagliflozin Viatris Den Europæiske Union - dansk - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotika anvendt i diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Madopar Depot 100+25 mg depotkapsler, hårde Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

madopar depot 100+25 mg depotkapsler, hårde

2care4 aps - benserazidhydrochlorid, levodopa - depotkapsler, hårde - 100+25 mg

Hexacima Den Europæiske Union - dansk - EMA (European Medicines Agency)

hexacima

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) er angivet til primær og booster nødvaccination, som spædbørn og småbørn fra seks uger mod difteri, stivkrampe, kighoste, hepatitis b, polio og invasive sygdomme forårsaget af haemophilus influenzae type b (hib). brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Hexyon Den Europæiske Union - dansk - EMA (European Medicines Agency)

hexyon

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vacciner - hexyon (dtap-ipv-hb-hib) er angivet til primær og booster nødvaccination, som spædbørn og småbørn fra seks uger mod difteri, stivkrampe, kighoste, hepatitis b, polio og invasive sygdomme forårsaget af haemophilus influenzae type b (hib). brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.